The 56th American Society of Hematology annual meeting: advances in clinical trials on relapse/refractory acute myeloid leukemia

Acute myeloid leukemia (AML) is a kind of heterogeneous disease. Whether the disease is relapse/refractory (R/R) or not, therapeutic effects are often poor. Now, it is still lack of effective therapy to solve this problem. With the in-depth study of the pathogenesis of AML, new chemotherapy drugs and chemotherapy combination emerge in an unending flow. The 56th American Society of Hematology (ASH) shares results of R/R AML clinical studies, which opening up new prospects for R/R AML treatment. Key words: Leukemia, myeloid, acute; Recurrence; Clinical trial